JP7588077B2 - Ｇｐｒ３５モジュレーター - Google Patents

Ｇｐｒ３５モジュレーター Download PDF

Info

Publication number
JP7588077B2
JP7588077B2 JP2021543122A JP2021543122A JP7588077B2 JP 7588077 B2 JP7588077 B2 JP 7588077B2 JP 2021543122 A JP2021543122 A JP 2021543122A JP 2021543122 A JP2021543122 A JP 2021543122A JP 7588077 B2 JP7588077 B2 JP 7588077B2
Authority
JP
Japan
Prior art keywords
alkyl
pharma
solvate
ceutically acceptable
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021543122A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022518523A5 (https=
JP2022518523A (ja
Inventor
ヒグチ，ロバート
Original Assignee
プロメテウス バイオサイエンシーズ，インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by プロメテウス バイオサイエンシーズ，インク． filed Critical プロメテウス バイオサイエンシーズ，インク．
Publication of JP2022518523A publication Critical patent/JP2022518523A/ja
Publication of JP2022518523A5 publication Critical patent/JP2022518523A5/ja
Application granted granted Critical
Publication of JP7588077B2 publication Critical patent/JP7588077B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2021543122A 2019-01-24 2020-01-23 Ｇｐｒ３５モジュレーター Active JP7588077B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962796459P 2019-01-24 2019-01-24
US62/796,459 2019-01-24
US201962873703P 2019-07-12 2019-07-12
US62/873,703 2019-07-12
US201962928223P 2019-10-30 2019-10-30
US62/928,223 2019-10-30
PCT/US2020/014777 WO2020154492A1 (en) 2019-01-24 2020-01-23 Gpr35 modulators

Publications (3)

Publication Number Publication Date
JP2022518523A JP2022518523A (ja) 2022-03-15
JP2022518523A5 JP2022518523A5 (https=) 2023-02-07
JP7588077B2 true JP7588077B2 (ja) 2024-11-21

Family

ID=71733100

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021543122A Active JP7588077B2 (ja) 2019-01-24 2020-01-23 Ｇｐｒ３５モジュレーター

Country Status (13)

Country Link
US (2) US11053251B2 (https=)
EP (1) EP3914256B1 (https=)
JP (1) JP7588077B2 (https=)
KR (1) KR102863894B1 (https=)
CN (1) CN113631168B (https=)
AU (1) AU2020210930B2 (https=)
BR (1) BR112021014566A2 (https=)
CA (1) CA3127786A1 (https=)
IL (1) IL285074B2 (https=)
MA (1) MA54825A (https=)
MX (1) MX2021008941A (https=)
TW (1) TWI845600B (https=)
WO (1) WO2020154492A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI845600B (zh) 2019-01-24 2024-06-21 美商普羅米修斯生物科學股份有限公司 Gpr35調節劑
AU2020275413A1 (en) 2019-05-14 2021-12-23 Cedars-Sinai Medical Center TL1A patient selection methods, systems, and devices
EP4185379A4 (en) * 2020-07-23 2023-11-22 Prometheus Biosciences, Inc. Therapeutic agents targeting gpr35
WO2023205463A1 (en) 2022-04-22 2023-10-26 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
GB202303387D0 (en) * 2023-03-08 2023-04-19 Thirtyfivebio Ltd Compounds

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004035584A1 (fr) 2002-10-16 2004-04-29 Universite Louis Pasteur Composes pharmaceutiques inhibiteurs specifiques de la pde5 du muscle lisse, compositions pharmaceutiques les contenant et utilisations therapeutiques
WO2005085867A2 (en) 2004-02-27 2005-09-15 Pfizer Japan, Inc. Screening method for emulators of neural activity and digestive system using gpr35

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005119252A2 (en) * 2004-05-26 2005-12-15 Arena Pharmaceuticals, Inc. Modulators of gpr35 for the treatment of metabolic-related disorders
GB1338235A (en) * 1970-12-15 1973-11-21 May & Baker Ltd Azapurinones
GB1421970A (en) * 1973-06-12 1976-01-21 May & Baker Ltd 8-azapurin-6-one derivatives
US4052390A (en) * 1973-06-12 1977-10-04 May & Baker Limited Azapurinones
GB1561345A (en) 1976-10-22 1980-02-20 May & Baker Ltd 8 - azapuring - 6 - ones
US4923874A (en) 1988-07-21 1990-05-08 G. D. Searle & Co. Use of 8-azapurin-6-one derivatives for control of hypertension
US5474796A (en) 1991-09-04 1995-12-12 Protogene Laboratories, Inc. Method and apparatus for conducting an array of chemical reactions on a support surface
US20070287630A1 (en) 2006-06-12 2007-12-13 Driwater, Inc. Moisturizing agent with nutrients
WO2012167053A1 (en) * 2011-06-01 2012-12-06 Janus Biotherapeutics, Inc. Novel immune system modulators
SG11201600853UA (en) 2013-08-05 2016-03-30 Twist Bioscience Corp De novo synthesized gene libraries
US20150273088A1 (en) * 2014-03-28 2015-10-01 Washington University Zaprinast analogues as glutaminase inhibitors and methods to predict response thereto
KR102481020B1 (ko) 2014-06-29 2022-12-26 프로파일 프러덕츠 엘엘씨 나무껍질 및 목재 섬유 성장 배지
WO2018195328A1 (en) * 2017-04-20 2018-10-25 Cedars-Sinai Medical Center Methods of predicting non-response to anti-tnf treatment in subjects with inflammatory bowel disease
WO2019210203A1 (en) 2018-04-27 2019-10-31 Cedars-Sinai Medical Center Compositions and methods of targeting gpr35 for the treatment of inflammatory bowel conditions
TWI845600B (zh) 2019-01-24 2024-06-21 美商普羅米修斯生物科學股份有限公司 Gpr35調節劑
EP3920953A4 (en) 2019-02-08 2022-12-14 Cedars-Sinai Medical Center METHODS, SYSTEMS AND KITS FOR THE TREATMENT OF INFLAMMATORY DISEASES TARGETED FOR IL18R1
WO2020163713A1 (en) 2019-02-08 2020-08-13 Cedars-Sinai Medical Center Methods, systems, and kits for treating inflammatory disease targeting skap2
AU2020275413A1 (en) 2019-05-14 2021-12-23 Cedars-Sinai Medical Center TL1A patient selection methods, systems, and devices
CA3162905A1 (en) 2019-11-27 2021-06-03 Cedars-Sinai Medical Center Predicting extraintestinal manifestations of inflammatory bowel disease
EP4185379A4 (en) 2020-07-23 2023-11-22 Prometheus Biosciences, Inc. Therapeutic agents targeting gpr35
AU2021377688A1 (en) 2020-11-13 2023-06-29 Cedars-Sinai Medical Center Methods, systems, and kits for treatment of inflammatory diseases targeting tl1a
WO2022140283A1 (en) 2020-12-21 2022-06-30 Cedars-Sinai Medical Center Tl1a therapy compositions and methods of treatment therewith

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004035584A1 (fr) 2002-10-16 2004-04-29 Universite Louis Pasteur Composes pharmaceutiques inhibiteurs specifiques de la pde5 du muscle lisse, compositions pharmaceutiques les contenant et utilisations therapeutiques
WO2005085867A2 (en) 2004-02-27 2005-09-15 Pfizer Japan, Inc. Screening method for emulators of neural activity and digestive system using gpr35

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Journal of Pharmacology and Experimental Therapeutics，2012年，Vol. 343，pp. 683-695

Also Published As

Publication number Publication date
US20210380590A1 (en) 2021-12-09
CA3127786A1 (en) 2020-07-30
CN113631168A (zh) 2021-11-09
CN113631168B (zh) 2024-11-19
MX2021008941A (es) 2021-10-13
EP3914256B1 (en) 2024-05-29
WO2020154492A1 (en) 2020-07-30
US20200239476A1 (en) 2020-07-30
KR20210119485A (ko) 2021-10-05
US11773101B2 (en) 2023-10-03
IL285074A (en) 2021-09-30
MA54825A (fr) 2021-12-01
IL285074B1 (en) 2024-08-01
EP3914256A4 (en) 2022-09-28
AU2020210930B2 (en) 2025-08-14
EP3914256A1 (en) 2021-12-01
IL285074B2 (en) 2024-12-01
TW202043234A (zh) 2020-12-01
TWI845600B (zh) 2024-06-21
BR112021014566A2 (pt) 2022-01-04
JP2022518523A (ja) 2022-03-15
AU2020210930A1 (en) 2021-09-09
US11053251B2 (en) 2021-07-06
KR102863894B1 (ko) 2025-09-23

Similar Documents

Publication Publication Date Title
JP7588077B2 (ja) Ｇｐｒ３５モジュレーター
US11884680B2 (en) Bromodomain inhibitors
JP5806417B2 (ja) Ｍｇａｔ２阻害剤としてのアリールジヒドロピリジノンおよびピペリジノン
TWI770527B (zh) Cot 調節劑及其使用方法
TWI853704B (zh) Lpa受體拮抗劑及其用途
CA2890981A1 (en) Amide-substituted heterocyclic compounds useful as modulators of il-12, il-23 and/or ifn.alpha. responses
CN112898289B (zh) 调节fxr活性的化合物及其应用
US20230151017A1 (en) Therapeutic agents targeting gpr35
CN117843521A (zh) 一种作为甲状腺激素β受体激动剂的化合物及其制备方法、应用
EA048936B1 (ru) Модуляторы gpr35
WO2025064325A1 (en) Gpr35 modulators
HK40059523A (en) Gpr35 modulators
EA046637B1 (ru) Соединения для модуляции активности fxr и их применение

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210820

RD12 Notification of acceptance of power of sub attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7432

Effective date: 20230110

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230123

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230123

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230110

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20231221

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240116

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20240116

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20240116

RD14 Notification of resignation of power of sub attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7434

Effective date: 20240116

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240416

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240703

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240918

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241028

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241111

R150 Certificate of patent or registration of utility model

Ref document number: 7588077

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150